Cyclosporine
- Generic Name
- Cyclosporine
- Brand Names
- Cequa, Gengraf, Neoral, Restasis, Sandimmune, Verkazia, Vevye, Ikervis
- Drug Type
- Small Molecule
- Chemical Formula
- C62H111N11O12
- CAS Number
- 59865-13-3
- Unique Ingredient Identifier
- 83HN0GTJ6D
- Background
Cyclosporine is a calcineurin inhibitor known for its immunomodulatory properties that prevent organ transplant rejection and treat various inflammatory and autoimmune conditions. It is isolated from the fungus Beauveria nivea. Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now available in various products by Novar...
- Indication
Cyclosporine is approved for a variety of conditions. Firstly, it is approved for the prophylaxis of organ rejection in allogeneic kidney, liver, and heart transplants. It is also used to prevent bone marrow transplant rejection. For the above indications, cyclosporine can be used in conjunction with azathioprine and corticosteroids. Finally, cyclosporine ca...
- Associated Conditions
- Atopic Dermatitis, Bone Marrow Transplant Rejection, Chronic transplant rejection, Connective Tissue Disorders, Dry Eyes, Graft-versus-host Disease (GVHD), Heart Transplant Rejection, Immune Thrombocytopenia (ITP), Interstitial Cystitis, Juvenile Idiopathic Arthritis (JIA), Kidney Transplant Rejection, Liver Transplant Rejection, Lupus Nephritis, Nephrotic Syndrome, Ocular Rosacea, Rheumatoid Arthritis, Severe Ulcerative Colitis, Steroid Dependent Nephrotic Syndrome, Steroid Resistant Nephrotic Syndrome, Uveitis, Vernal Keratoconjunctivitis, Blistering disorder, Refractory Ulcerative colitis, Severe Psoriasis, Severe, active Rheumatoid arthritis, Severe, recalcitrant Plaque psoriasis, Suppressed tear production
- Associated Therapies
- -
Gemtuzumab Ozogamicin, Fludarabine, and Total-body Irradiation Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome
- Conditions
- First Posted Date
- 2004-03-25
- Last Posted Date
- 2010-04-02
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Registration Number
- NCT00008151
- Locations
- ๐บ๐ธ
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myeloid Leukemia
- Conditions
- First Posted Date
- 2004-03-19
- Last Posted Date
- 2010-03-30
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 100
- Registration Number
- NCT00002789
- Locations
- ๐บ๐ธ
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
S9920 Busulfan Compared With Cyclophosphamide in Patients Undergoing Total-Body Irradiation Plus Peripheral Stem Cell Transplantation for Advanced Myelodysplastic Syndrome or Related Acute Myeloid Leukemia
- First Posted Date
- 2004-03-16
- Last Posted Date
- 2015-03-06
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 240
- Registration Number
- NCT00005866
- Locations
- ๐บ๐ธ
University of Mississippi Medical Center, Jackson, Mississippi, United States
๐บ๐ธCCOP - Virginia Mason Research Center, Seattle, Washington, United States
๐บ๐ธSt. Louis University Health Sciences Center, Saint Louis, Missouri, United States
Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant
- Conditions
- Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Nasal Type Extranodal NK/T-cell LymphomaChildhood Myelodysplastic SyndromesChildhood Nasal Type Extranodal NK/T-cell LymphomaChronic Myelomonocytic LeukemiaAccelerated Phase Chronic Myelogenous LeukemiaAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAnaplastic Large Cell LymphomaAngioimmunoblastic T-cell Lymphoma
- Interventions
- First Posted Date
- 2004-03-09
- Last Posted Date
- 2020-01-18
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 37
- Registration Number
- NCT00078858
- Locations
- ๐บ๐ธ
Stanford University Hospitals and Clinics, Stanford, California, United States
๐บ๐ธRocky Mountain Cancer Centers-Midtown, Denver, Colorado, United States
๐บ๐ธEmory University/Winship Cancer Institute, Atlanta, Georgia, United States
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia or Myelodysplastic Syndrome
- Conditions
- First Posted Date
- 2004-02-16
- Last Posted Date
- 2010-04-02
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Registration Number
- NCT00027924
- Locations
- ๐บ๐ธ
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
- Conditions
- Acute Lymphoblastic Leukemia in RemissionRefractory Hodgkin LymphomaWaldenstrom MacroglobulinemiaAcute Myeloid Leukemia in RemissionAggressive Non-Hodgkin LymphomaChronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveHematopoietic and Lymphoid Cell NeoplasmDiffuse Large B-Cell LymphomaIndolent Non-Hodgkin LymphomaMantle Cell Lymphoma
- Interventions
- First Posted Date
- 2004-01-12
- Last Posted Date
- 2017-05-15
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 87
- Registration Number
- NCT00075478
- Locations
- ๐บ๐ธ
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
๐บ๐ธVA Puget Sound Health Care System, Seattle, Washington, United States
๐ฉ๐ชMedizinische Univ Klinik Koln, Koln, Germany
Radiolabeled Monoclonal Antibody Therapy, Fludarabine Phosphate, and Low-Dose Total-Body Irradiation Followed by Donor Stem Cell Transplant and Immunosuppression Therapy in Treating Older Patients With Advanced Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
- Conditions
- Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Previously Treated Myelodysplastic SyndromesRefractory Anemia With Excess BlastsAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Inv(16)(p13;q22)Recurrent Adult Acute Myeloid LeukemiaSecondary Myelodysplastic SyndromesUntreated Adult Acute Myeloid LeukemiaAdult Acute Myeloid Leukemia With t(15;17)(q22;q12)Chronic Myelomonocytic Leukemia
- Interventions
- Radiation: iodine I 131 monoclonal antibody BC8Radiation: total-body irradiationProcedure: allogeneic hematopoietic stem cell transplantationProcedure: peripheral blood stem cell transplantationDrug: fludarabine phosphateDrug: cyclosporineDrug: mycophenolate mofetilOther: laboratory biomarker analysis
- First Posted Date
- 2003-12-12
- Last Posted Date
- 2019-11-13
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 79
- Registration Number
- NCT00008177
- Locations
- ๐บ๐ธ
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Allogeneic Stem Cell Transplant After ATG, High-Dose Melphalan, and Fludarabine for Patients With Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-12-11
- Last Posted Date
- 2023-06-05
- Lead Sponsor
- University of California, San Diego
- Target Recruit Count
- 5
- Registration Number
- NCT00074269
- Locations
- ๐บ๐ธ
Rebecca and John Moores UCSD Cancer Center, La Jolla, California, United States
Graft-Versus-Host Disease in Treating Patients With Recurrent or Refractory Lymphoma or Hodgkin's Disease
- Conditions
- First Posted Date
- 2003-12-02
- Last Posted Date
- 2015-07-20
- Target Recruit Count
- 50
- Registration Number
- NCT00003414
- Locations
- ๐บ๐ธ
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Chemotherapy Plus Bone Marrow Transplantation in Treating Patients With Metastatic Melanoma
- Conditions
- First Posted Date
- 2003-11-25
- Last Posted Date
- 2020-06-30
- Target Recruit Count
- 6
- Registration Number
- NCT00003060
- Locations
- ๐บ๐ธ
Louisiana State University School of Medicine, Shreveport, Louisiana, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.